Planet Green Holdings Corp. subsidiary Taihe Bio has entered a technology transfer agreement with Harbin Aikesailun Biotechnology to acquire the formulation and registration rights for an immune-support chewable tablet. The product combines lactoferrin, bovine colostrum, and vitamin C, with the company planning an asset-light manufacturing model to enter the Chinese health food market.
Subsidiary Taihe Bio agreed to acquire the formulation, production technology and Chinese health food registration rights for a lactoferrin, bovine colostrum and vitamin C chewable tablet. The 8-K discloses no purchase price, no revenue figures and no financial guidance, so the deal cannot be quantified as materially positive or negative. It extends the previously announced lactoferrin strategy and remains subject to SAMR approval of the registration transfer.
- • Technology transfer agreement with Harbin Aikesailun Biotechnology announced November 17, 2026
- • Pending joint application to SAMR to transfer the Chinese health food registration certificate to Taihe Bio
- • No purchase price or financial terms are disclosed, so the cost and expected return are unknown
- • Transfer of the registration certificate remains subject to regulatory approval